iVeena Delivery Systems Announces Key Leadership Promotions

Moves strengthen operational leadership and advance scientific vision for lead asset IVMED-85

Published on Feb. 4, 2026

Got story updates? Submit your updates here. ›

iVeena Delivery Systems, a clinical-stage ophthalmology company, has announced key executive promotions to bolster its organizational capabilities and accelerate development of its lead asset, IVMED-85, a first-in-class investigational eye drop for pediatric myopia. Michael Burr has been promoted to Chief Operating Officer, and Sarah Molokhia has been promoted to Chief Scientific Officer, while former COO Ned Weinshenker is moving into the role of Vice President of Chemistry, Manufacturing, & Controls.

Why it matters

These strategic promotions reflect iVeena's commitment to scaling its operations and advancing its scientific vision as it prepares to initiate a Phase 1 study for IVMED-85, its lead asset targeting pediatric myopia, a growing public health concern.

The details

The timing of the promotions coincides with the anticipated initiation of a Phase 1 study for IVMED-85 in healthy adult volunteers. iVeena previously had a positive engagement with the FDA resulting in an open investigational new drug (IND) application for the program, and study enrollment is expected to begin in February 2026.

  • iVeena's promotions are effective immediately.
  • The Phase 1 study for IVMED-85 is expected to begin enrollment in February 2026.

The players

Michael Burr

Promoted to Chief Operating Officer at iVeena Delivery Systems. He has over 15 years of experience in ocular drug delivery and device development, and previously served as Vice President of Product Development at iVeena.

Sarah Molokhia

Promoted to Chief Scientific Officer at iVeena Delivery Systems. She has spearheaded critical research in ocular drug delivery, including IND-enabling work for IVMED-85 and securing competitive grant funding to support preclinical progress in myopia control.

Ned Weinshenker

Former Chief Operating Officer at iVeena Delivery Systems, now moving into the role of Vice President of Chemistry, Manufacturing, & Controls.

Barry Hannover

Co-Chair of the Board of iVeena Delivery Systems.

IVMED-85

iVeena's lead program, a new chemical entity (NCE), preservative-free prescription eye drop to prevent myopic progression.

Got photos? Submit your photos here. ›

What they’re saying

“Michael and Sarah are outstanding leaders whose contributions have been integral to iVeena's progress. As we enter the clinical phase of product development these promotions position the company for even greater success in bringing disease-modifying ophthalmic therapies to patients worldwide.”

— Barry Hannover, Co-Chair of the Board of iVeena

What’s next

iVeena expects to begin enrollment for the Phase 1 study of IVMED-85 in healthy adult volunteers in February 2026.

The takeaway

These strategic leadership promotions at iVeena Delivery Systems demonstrate the company's commitment to scaling its operations and advancing its scientific vision as it prepares to initiate clinical development of its lead asset, IVMED-85, a first-in-class eye drop for pediatric myopia, a growing public health concern.